June 18, 2013
New Malaria Crisis Presents Opportunity For Plandai
In a recent feature story published in The Atlantic in early June, an estimated one-third of all malaria drugs in some African countries may be counterfeit or sub-standard. In fact, the proliferation of fake malaria and other drugs on the continent may cause malaria to reach epidemic proportions in some areas already traditionally hit by the disease. These events are a potential disaster for the hundreds of millions people living in areas at risk of malaria transmission in Africa and it could prompt a spike in the estimated 600,000 deaths from the disease this year occurring in the African Region.
However, this crisis may be aided by Plandai Biotechnology, Inc. (OTCQB – PLPL - $0.52 – Spec Buy) which has made great strides toward treating and preventing malaria. In a recent study, the Company's Phytofare™ Catechin Extract proved effective in killing the malaria parasite, plasmodium falciparum. In the study, the single and most dominant catechin - Epigallocatechin Gallate (EGCG) - was isolated from Plandai's Phytofare™ extract and its effectiveness compared in killing the P. falciparum parasite against a purified EGCG extract. The results, which are expected to be published soon, showed that the Phytofare™ extract killed the parasite and with a lower dosage than the purified EGCG extract.
This study involving Phytofare™ is the first to show the effectiveness of using a commercial botanical extract, rather than purified extract of EGCG catechin, as an anti-malarial.
These results validate the Company’s decade-long research into the opportunity for using botanical extracts as a means to combat one of the world's great plagues. Plandai is finalizing agreements to undertake further in vitro and animal studies to further validate the antimalarial drug target through greater synergistic activity of the complete Phytofare™ catechin complex containing the total eight catechins, rather than the single isolated Epigallocatechin Gallate (EGCG).
Pending a successful outcome, the Company plans to immediately seek FDA approval to commence human clinical trials in 2014. However, under the circumstances, it is possible that Plandai seeks to accelerate the process in order to assist in stemming the current crisis.
If the Company is successful in developing a treatment or preventive vehicle for malaria, it could be a very profitable and very swift game-changer for the Company given its South Africa plantation and botanical-based therapeutic and go a long way toward cost-effectively eliminating one of the world’s most severe health issues. Plus, given the form and type of treatment, it is unlikely that counterfeit or false Plandai products would be produced, which would provide both a clinical and ethical benefit to those at risk.
For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
Senior Analyst: Robert Goldman
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.